Search Results - "Moffa, Simona"

Refine Results
  1. 1

    Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives by Cefalo, Chiara Maria Assunta, Cinti, Francesca, Moffa, Simona, Impronta, Flavia, Sorice, Gian Pio, Mezza, Teresa, Pontecorvi, Alfredo, Giaccari, Andrea

    Published in Cardiovascular diabetology (28-02-2019)
    “…Sotagliflozin is a dual sodium-glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D)…”
    Get full text
    Journal Article
  2. 2

    Potential cause-effect relationship between insulin autoimmune syndrome and alpha lipoic acid: Two case reports by Moffa, Simona, Improta, Ilaria, Rocchetti, Sandro, Mezza, Teresa, Giaccari, Andrea

    “…•We here report two new cases of insulin autoimmune syndrome (IAS) triggered by alpha lipoic acid in two Caucasian women.•This new cases are associated with…”
    Get full text
    Journal Article
  3. 3

    Alpha-Lipoic Acid and Glucose Metabolism: A Comprehensive Update on Biochemical and Therapeutic Features by Capece, Umberto, Moffa, Simona, Improta, Ilaria, Di Giuseppe, Gianfranco, Nista, Enrico Celestino, Cefalo, Chiara M A, Cinti, Francesca, Pontecorvi, Alfredo, Gasbarrini, Antonio, Giaccari, Andrea, Mezza, Teresa

    Published in Nutrients (21-12-2022)
    “…Alpha-lipoic acid (ALA) is a natural compound with antioxidant and pro-oxidant properties which has effects on the regulation of insulin sensitivity and…”
    Get full text
    Journal Article
  4. 4
  5. 5

    The Interplay between Immune System and Microbiota in Diabetes by Giaccari, Andrea, Pontecorvi, Alfredo, Santoro, Antonio, Sorice, Gian Pio, Impronta, Flavia, Cinti, Francesca, Cefalo, Chiara M. A., Mezza, Teresa, Moffa, Simona, Di Giuseppe, Gianfranco

    Published in Mediators of inflammation (2019)
    “…Diabetes is not a single and homogeneous disease, but a cluster of metabolic diseases characterized by the common feature of hyperglycemia. The pathogenesis of…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date by Cinti, Francesca, Moffa, Simona, Impronta, Flavia, Cefalo, Chiara Ma, Sun, Vinsin A, Sorice, Gian Pio, Mezza, Teresa, Giaccari, Andrea

    Published in Drug design, development and therapy (01-01-2017)
    “…Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the latest therapeutic strategy in the treatment of type 2 diabetes mellitus (T2DM). Using an…”
    Get full text
    Journal Article
  8. 8

    Effects of PCSK9 inhibition on glucose metabolism and β-cell function in humans: a pilot study by Moffa, Simona, Mezza, Teresa, Ferraro, Pietro Manuel, Di Giuseppe, Gianfranco, Cefalo, Chiara M A, Cinti, Francesca, Impronta, Flavia, Capece, Umberto, Ciccarelli, Gea, Mari, Andrea, Pontecorvi, Alfredo, Giaccari, Andrea

    Published in Frontiers in endocrinology (Lausanne) (31-05-2023)
    “…Anti-PCSK9 monoclonal antibodies are effective in reducing LDL-C and cardiovascular events by neutralizing circulating PCSK9. PCSK9, however, is also expressed…”
    Get full text
    Journal Article
  9. 9
  10. 10

    108-OR: Insulin Resistance Is Associated with Alterations in the Dynamics of Incretin Secretion by Di Giuseppe, Gianfranco, Soldovieri, Laura, Ciccarelli, Gea, Brunetti, Michela, Cinti, Francesca, Moffa, Simona, Holst, Jens J, Giaccari, Andrea, Mezza, Teresa

    Published in Diabetes (New York, N.Y.) (01-06-2024)
    “…GIP and GLP-1 exert a fundamental role in glucose homeostasis, but it is still debated if modifications in GIP and GLP-1 secretion can affect the metabolic…”
    Get full text
    Journal Article
  11. 11

    Why do some glucose-lowering agents improve non-alcoholic fatty liver disease whereas others do not? A narrative review in search of a unifying hypothesis by Ciccarelli, Gea, Di Giuseppe, Gianfranco, Cinti, Francesca, Moffa, Simona, Mezza, Teresa, Giaccari, Andrea

    Published in Diabetes/metabolism research and reviews (01-10-2023)
    “…Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D) are metabolic disorders connected by common pathophysiological mechanisms. Since insulin…”
    Get full text
    Journal Article
  12. 12

    1559-P: Heterogeneity of Trajectories of Metabolic Parameters after 50% Beta-Cell Mass Loss by Pancreatectomy by BIZZOTTO, ROBERTO, DI GIUSEPPE, GIANFRANCO, SOLDOVIERI, LAURA, CINTI, FRANCESCA, MOFFA, SIMONA, BRUNETTI, MICHELA, CICCARELLI, GEA, ALFIERI, SERGIO, QUERO, GIUSEPPE, MARI, ANDREA, GIACCARI, ANDREA, MEZZA, TERESA

    Published in Diabetes (New York, N.Y.) (14-06-2024)
    “…Temporal trajectories of metabolic parameters in the onset of dysglycemia are heterogeneous. We aimed to characterize the temporal trajectories of metabolic…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20

    2110-P: Correlation between Ex Vivo Islet Proteomic Analysis and In Vivo Secretory Function in Humans by ASSUNTA CEFALO, CHIARA MARIA, MEZZA, TERESA, CINTI, FRANCESCA, MOFFA, SIMONA, CAPECE, UMBERTO, KULKARNI, ROHIT, GIACCARI, ANDREA

    Published in Diabetes (New York, N.Y.) (01-06-2020)
    “…Insulin resistance and β-cell dysfunction are the main actors in the pathogenesis of type 2 diabetes mellitus, causing both quantitative and qualitative loss…”
    Get full text
    Journal Article